Recent News

• 03.19.2025 - scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call
• 03.19.2025 - scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.19.2025 - scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.12.2025 - scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
• 03.12.2025 - scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
• 03.11.2025 - Leerink's Global Biopharma Conference 2025
• 03.06.2025 - scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
• 03.06.2025 - scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
• 03.05.2025 - TD Cowen 45th Annual Health Care Conference
• 02.26.2025 - scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Recent Filings

• 03.19.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.19.2025 - 8-K Current report
• 03.19.2025 - EX-99.1 EX-99.1
• 03.19.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.31.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.28.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors